Current Treatment Options in Neurology

, Volume 9, Issue 1, pp 48–54

Optic neuritis: The role of disease-modifying therapy disease-modifying therapy in this clinically isolated syndrome

Article
  • 42 Downloads

Opinion statement

Optic neuritis (ON) is an important clinical entity, which may herald the diagnosis of multiple sclerosis (MS). Patients with acute monosymptomatic ON generally have a good visual prognosis, and the speed of recovery may be hastened with intravenous methylprednisolone. The question of whether disease-modifying therapy should be initiated after ON as a clinically isolated syndrome is a controversial topic, and factors specific to the patient should be taken into consideration before weighing in favor or against this therapeutic option. A significant proportion of patients with ON will go on to develop MS, and early initiation of therapy may delay this diagnosis. In addition, disease-modifying therapies also may reduce the disabling effects of MS among patients, but this is unknown. There are approved therapies currently available for patients with ON and an abnormal baseline cranial MRI scan, which predict a greater risk of future MS. Patients with a higher baseline MRI burden of disease, multifocal symptomatology (including sensory complaints) at onset, a high relapse rate, and a rapid accumulation of disability within the first few years of diagnosis may benefit from early and aggressive therapy with the disease-modifying drugs that are currently available. ON patients with few or no lesions on their baseline MRI scans and those with low rates of clinical relapse may be selected for careful clinical follow-up and monitored for signs of disease activity before the role of disease-modifying therapy is determined. ON patients with no light perception vision at presentation, marked optic disc swelling, and other atypical clinical features (including peripapillary hemorrhages or retinal exudates) may have a reduced risk of future MS, and for these patients, disease-modifying therapy may be deferred until it is deemed necessary by the patient and the treating physician.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Nilsson P, Larsson EM, Maly-Sundgren P, et al.: Predicting the outcome of optic neuritis—evaluation of risk factors after 30 years of follow up. J Neurol 2005, 252:396–402.PubMedCrossRefGoogle Scholar
  2. 2.
    Soderstrom M: Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand 2001, 79:223–227.PubMedCrossRefGoogle Scholar
  3. 3.
    Miller D, Barkhof F, Montalban X, et al.: Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurol 2005, 4:281–288.PubMedCrossRefGoogle Scholar
  4. 4.
    Frohman EM, Frohman TC, Zee DS, et al.: The neuroophthalmology of multiple sclerosis. Lancet Neurol 2005, 4:111–121.PubMedCrossRefGoogle Scholar
  5. 5.
    Hickman SJ, Dalton CM, Miller DH: Management of acute optic neuritis. Lancet 2002, 360:1953–1962.PubMedCrossRefGoogle Scholar
  6. 6.
    Soderstrom M, Ya-Ping J, Hillert J: Optic neuritis prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998, 50:708–714.PubMedGoogle Scholar
  7. 7.
    Cree BAC, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105–122.PubMedCrossRefGoogle Scholar
  8. 8.
    Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 354:2106–2112.CrossRefGoogle Scholar
  9. 9.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999, 53:1107–1114.PubMedGoogle Scholar
  10. 10.
    Macfayden DJ, Drance SM, Douglas GR, et al.: The retinal nerve fiber layer, neuroretinal rim area, and visual evoked potential in MS. Neurology 1988, 38:1353–1358.Google Scholar
  11. 11.
    Sisto D, Trojano M, Vetrugno M, et al.: Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 2005, 4:1264–1268.CrossRefGoogle Scholar
  12. 12.
    Acar G, Ozakbas S, Cakmakci H, et al.: Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement. Int J Neurosci 2004, 114:1025–1033.PubMedCrossRefGoogle Scholar
  13. 13.
    Hood DC, Odel JG, Zhang X: Tracking the recovery of local optic nerve function after optic neuritis: a multifocal VEP study. Invest Ophthalmol Vis Sci 2000, 41:4032–4038.PubMedGoogle Scholar
  14. 14.
    Simon JH, McDonald WI: Assessment of optic nerve damage in multiple sclerosis using magnetic resonance imaging. J Neurol Sci 2000, 172:S23–S26.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller D, Barkhof F, Montalban X, et al.: Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005, 4:341–348.PubMedCrossRefGoogle Scholar
  16. 16.
    Hickman SJ, Toosy AT, Jones SJ, et al.: A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004, 127:2498–2505.PubMedCrossRefGoogle Scholar
  17. 17.
    Eggenberger ER: Inflammatory optic neuropathies. Ophthalmol Clin North Am 2001, 14:73–82.PubMedGoogle Scholar
  18. 18.
    Optic Neuritis Study Group: The five-year risk of multiple sclerosis after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997, 49:1404–1413.Google Scholar
  19. 19.
    Optic Neuritis Study Group: High and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 2003, 121:944–949.CrossRefGoogle Scholar
  20. 20.
    Parisi V, Manni G, Spadaro M, et al.: Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999, 40:2520–2527.PubMedGoogle Scholar
  21. 21.
    Trip SA, Schlottmann PG, Jones SJ, et al.: Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005, 58:383–391.PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher JB, Jacobs DA, Markowitz CE, et al.: Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006, 113:324–332.PubMedCrossRefGoogle Scholar
  23. 23.
    Costello F, Coupland S, Hodge W, et al.: Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006, 59:963–969.PubMedCrossRefGoogle Scholar
  24. 24.
    Beck RW, Cleary PA, Anderson MM: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581–588.PubMedCrossRefGoogle Scholar
  25. 25.
    Optic Neuritis Study Group: The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991, 109:1673–1678.Google Scholar
  26. 26.
    Van Stavern GP: Management of optic neuritis and multiple sclerosis. Curr Opin Ophthalmol 2001, 12:400–407.PubMedCrossRefGoogle Scholar
  27. 27.
    Kaufman DI, Trobe JD, Eggenberger ER: Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 2000, 54:2039–2044.PubMedGoogle Scholar
  28. 28.
    Beck RW, Smith CH, Gal RL et al.: Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004, 9:1386–1389.Google Scholar
  29. 29.
    Jacobs LD, Beck RW, Simon JH: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898–904.PubMedCrossRefGoogle Scholar
  30. 30.
    Comi G, Filippi M, Barkof F: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576–1582.PubMedCrossRefGoogle Scholar
  31. 31.
    Kappos L, Polman CH, Freedman MS, et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242–1249.PubMedCrossRefGoogle Scholar
  32. 32.
    Frohman EM, Havrdova E, Lublin F, et al.: Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006, 63:614–619.PubMedCrossRefGoogle Scholar
  33. 33.
    Pittock SJ, Weinshenker BG, Noseworthy JH, et al.: Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006, 63:611–614.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Neurology, The Ottawa Hospital, General CampusThe University of OttawaOttawaCanada

Personalised recommendations